Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually
relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a
cell surface receptor that expressed primarily by malignant and normal plasma cells. This is
a single-arm that includes escalation phase and expansion phase ,Selinexor in Combination
withThalidomide and Dexamethasone to Treat Relapsed/Refractory Multiple Myeloma Patients.To
evaluate efficacy and safety of Selinexor in combination with Thalidomide and Dexamethasone
in RRMM patients received at least one prior lines of therapy